

28 May 2020

DyeVert™ featured at the SCAI 2020 Scientific Session: Procedure-Based Strategies to reduce Contrast-Induced Acute Kidney Injury

Key Highlights

- Two hospitals published results of quality improvement programs focused on Contrast-Induced Acute Kidney Injury (CI-AKI) reduction by implementing guideline-driven, procedure-based strategies
- Key outcomes were:
 - Contrast reduction in DyeVert cases – lower total contrast volume delivered to patients and lower contrast volume relative to baseline kidney function
 - CI-AKI relative reduction of 84% and 57% seen in the respective hospitals quarterly reporting data
 - Number of patients needed-to-treat to avoid one CI-AKI event were 10 and 16
 - Hospital cost savings up to \$696 per procedure

Minnesota, United States and Melbourne, Australia – 28 May 2020 – Osprey Medical Inc. (ASX:OSP) (**Osprey or the Company**) is pleased to provide an update on 2 abstracts published at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Session 2020 held virtually on May 14 -16; this annual meeting brings together more than 2,000 interventional cardiology and cardiovascular professionals annually.

Osprey Medical’s President and CEO, Mike McCormick commented, “Hospital-acquired CI-AKI has devastating clinical consequences for patients and is a significant driver of added healthcare costs. We have the privilege of partnering with hospitals that are leading the nation in developing and implementing guideline-driven, procedure-based strategies to reduce CI-AKI in the Cath Lab. These 2 multidisciplinary hospital initiatives resulted in improved patient-centered care and reductions in hospital-acquired CI-AKI. Additionally, both programs resulted in overall cost savings for the hospitals. These outcomes add to the growing body of evidence that pragmatic, procedure-based, CI-AKI prevention strategies are feasible, generalizable, and consistently result in positive clinical and economic outcomes”

Both studies reported on the use of Osprey’s DyeVert Contrast Reduction System as part of a kidney care protocol in patients undergoing coronary angiography. According to these findings, absolute CI-AKI reduction was 10.46% and 6.47% respectively and a relative reduction of CI-AKI was reported at 83.7% and 57% respectively. Additional outcomes including contrast minimization and cost savings were also detailed with positive outcomes in these publications.

Title	Real-World Impact of A Quality Improvement Program for AKI Prevention in the Cardiac Cath Lab
Authors	Craig Turner, R.N. and Paul A Tucker, M.D.
Abstract	https://scai.confex.com/scai/2020/meetingapp.cgi/Paper/9151
Study	<ul style="list-style-type: none">• Protocol included screening, hydration and maximum allowable contrast thresholds• DyeVert was used in CKD or STEMI patients (kidney disease and heart attack patients)

Title **Reducing Contrast-Induced Acute Kidney Injury in a Cardiac Catherization Laboratory: A Quality Improvement Initiative**

Authors Amy Cameron, R.N. and Tanya J Espinosa, R.N.

Abstract <https://scai.confex.com/scai/2020/meetingapp.cgi/Paper/10856>

Study • Protocol included physician directed hydration, use of DyeVert in CKD patients and maximum allowable contrast thresholds

 • DyeVert was used in 423 cases

Eight US hospitals have now published real-world data showing CI-AKI reduction when using the DyeVert Contrast Reduction System as part of a kidney care protocol in the Cath Lab, adding to Osprey’s growing body of evidence.

This announcement has been approved by the President & Chief Executive Officer, Mike McCormick.

– ENDS –

Contact details:

Investors

Leijie Li
Vesparum Capital
T: (61) 3 8582 4800
ospreymed@vesparum.com

Company

Doug Schoenberg
Vice President of Marketing
T: (952) 955 8230
dschoenberg@ospreymed.com

About Osprey Medical (ASX: OSP)

Osprey Medical’s vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient’s risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (AKI). The Company’s core technologies originated from research conducted by Dr David Kaye at Melbourne’s Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company’s DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney diseases.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.